Ageing and cancer

Purificación Muñoz
PRINCIPAL INVESTIGATORS
  • Joan Maria Viñals Viñals
  • Juan Jesus Martin Liberal
CLINICAL RESEARCHERS
  • Rosa Maria Penin Mosquera
  • Diana Perez Sidelnikova
POSTDOCTORAL RESEARCHERS
  • Marta Lopez Cerda
  • Laura Lorenzo Sanz
CANCER
ONCOBELL

Scientific production

9

PAPERS

Average IF: 5,86

6

LED PAPERS

Average IF: 6,1

1 PUBLICATION IN FIRST DECILE

3 PUBLICATIONS IN FIRST QUARTILE

8 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Drakaki,A;Powles,T;Bamias,A;Martin Liberal,J;Shin,SJ;Friedlander,T;Tosi,D et al, Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)., Clin. Cancer Res., 2023;29(21):4373-4384, doi:10.1158/1078-0432.CCR-23-0798
  • Soto Castillo,JJ;Llavata Marti,L;Fort Culillas,R;Andreu Cobo,P;Moreno,R;Codony,C;del Muro,XG et al, SWI/SNF Complex Alterations in Tumors with Rhabdoid Features: Novel Therapeutic Approaches and Opportunities for Adoptive Cell Therapy, Int. J. Mol. Sci., 2023;24(13):doi:10.3390/ijms241311143
  • Creus Bachiller,E;Fernández Rodríguez,J;Magallón Lorenz,M;Ortega Bertran,S;Navas Rutete,S;Romagosa,C;Silva,TM et al, Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities, Mol. Oncol., 2023;doi:10.1002/1878-0261.13534
  • Manzano,JL;Martin Liberal,J;Fernandez Morales,LA;Benitez,G;Martinez,JM;Quindos,M;Garcia Castano,A et al, Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study, Melanoma Res., 2023;33(5):388-397, doi:10.1097/CMR.0000000000000888
  • Millán Esteban,D;García Casado,Z;Macià,A;de la Rosa,I;Torrecilla Llossera,C;Penín,RM;Manrique Silva,E et al, Molecular Profile of Subungual Melanoma: a MelaNostrum Consortium Study of 68 Cases Reporting BRAF, NRAS, KIT, and TERT promoter status., Dermatology, 2023;240(1):164-169, doi:10.1159/000534955

Research highlights

PROJECTS

1 Granted competitive projects
8 Ongoing competitive projects

8 Started clinical trials
29 Ongoing clinical trials
3 Ongoing non competitive projects

PUBLISHED WORKS

1 thesis

NETWORKS

EuroPDX
AGAUR SGR GRC

Selected projects

  • MCI21004. Estudio de nuevas estrategias terapéuticas para suprimir la resistencia a terapias basadas en el bloqueo de los puntos de control inmunitarios (ICB) en cSCC y HNSCCs avanzados. Ministerio de Ciencia e Innovación. Budget: 223.850€. 2021-2024. PI: MUÑOZ MORUNO, PURIFICACION.
  • FIS21126. Tratamiento con TILs en tumores avanzados con alteraciones del complejo SWI/SNF: El estudio TILTS. Instituto de Salud Carlos III (ISCIII). Budget: 1.081.914,72€. 2022-2025. PI: MARTIN LIBERAL, JUAN JESUS.
  • AGA22038. Nuevas terapias para el tratamiento de cáncer de piel
    Novel therapies for skin cancer treatment. AGENCIA GESTIO D’AJUTS UNIV. I RECERCA. Budget: 40.000€. 2022-2025. PI: MUÑOZ MORUNO, PURIFICACION; MARTIN LIBERAL, JUAN JESUS.
  • PSJ22017. INFLUENCIA DE LA PLASTICIDAD DE LAS CÉLULAS TUMORALES EN LA RESPUESTA AL TRATAMIENTO ADYUVANTE CON ANTI-PD-1 EN MELANOMA ESTADÍO IIIC/D RESECADO. Grupo Español Multidisciplinar de Melanoma (GEM). Budget: 20.000€. 2022-2024. PI: MARTIN LIBERAL, JUAN JESUS; MUÑOZ MORUNO, PURIFICACION.
  • 2023-020-1. Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group. Pierre Fabre Médicamen. Budget: 510.984€. 2022- . PI: MARTIN LIBERAL, JUAN JESUS.